<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04486885</url>
  </required_header>
  <id_info>
    <org_study_id>hj-20-ESCAI</org_study_id>
    <nct_id>NCT04486885</nct_id>
  </id_info>
  <brief_title>European Study of Cerebral Aspergillosis Treated With Isavuconazole</brief_title>
  <acronym>ESCAI</acronym>
  <official_title>European Study of Cerebral Aspergillosis Treated With Isavuconazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imagine Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imagine Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study clinical context Cerebral aspergillosis (CA) is a rare location of invasive&#xD;
      aspergillosis (IA), associated with a high morbidity and mortality. Since 2002, voriconazole&#xD;
      is the recommended first line treatment of invasive aspergillosis. More recently,&#xD;
      isavuconazole appeared to be not less effective than voriconazole in the treatment of&#xD;
      filamentous IFI, with a better tolerance profile.&#xD;
&#xD;
      The investigators aim to evaluate better the efficacy and the safety of isavuconazole in the&#xD;
      treatment of cerebral aspergillosis by a descriptive, multicentric, international&#xD;
      retrospective cohort study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Outcome of the patients : alive without CA treatment/alive under CA treatment/ deceased.</measure>
    <time_frame>At baseline</time_frame>
    <description>Number of patients alive without CA treatment/alive under CA treatment/ deceased.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monitoring of isavuconazole : dosage in the serum and in the cerebro-spinal-fluid</measure>
    <time_frame>At baseline</time_frame>
    <description>dosage of isavuconazole in the serum and in the cerebro-spinal-fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Adverse events under isavuconazole and drug interactions</measure>
    <time_frame>At baseline</time_frame>
    <description>Adverse events under isavuconazole and drug interactions</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cerebral Aspergillosis</condition>
  <condition>Invasive Aspergillosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        40 adult ou pediatric patients, suffering frome cerebral aspergillosis, diagnosed between&#xD;
        2017 and 2020, and treated by isavuconazole at least 7 days&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Proven or probable cerebral aspergillosis according to the EORTC criteria modified by&#xD;
             adding diabetes in the host criteria&#xD;
&#xD;
          -  In child or adult&#xD;
&#xD;
          -  Treated by isavuconazole at least 7 days&#xD;
&#xD;
          -  Diagnosed between March 2017 and June 2020&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Possible cerebral aspergillosis&#xD;
&#xD;
          -  isavuconazole treatment for less than 7 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fanny Lanternier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Necker</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fanny Lanternier, MD</last_name>
    <phone>01 44 49 52 62</phone>
    <email>fanny.lanternier@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fanny Lanternier, MD</last_name>
      <phone>01 44 49 52 62</phone>
      <email>fanny.lanternier@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2020</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cerebral aspergillosis</keyword>
  <keyword>isavuconazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

